Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden

Tushar Srivastava,Vimalanand S. Prabhu,Haojie Li,Ruifeng Xu,Natalie Zarabi,Yichen Zhong,James M. Pellissier,Rodolfo F. Perini,Ronald de Wit,Ronac Mamtani

European Urology Oncology（2020）

引用 12|浏览18

暂无评分

摘要

Pembrolizumab is associated with better quality of life and survival and is cost-effective compared to chemotherapy as second-line treatment for locally advanced or metastatic urothelial carcinoma in Sweden.

查看译文

关键词

Bladder cancer,Cost-effectiveness,Immunotherapy,Pembrolizumab,Urothelial carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要